- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst | 3 | Benzinga.com | ||
| 07.04. | TD Cowen initiates MapLight Therapeutics stock with buy rating | 1 | Investing.com | ||
| 07.04. | TD Cowen startet Coverage für MapLight Therapeutics mit Kaufempfehlung | 2 | Investing.com Deutsch | ||
| 26.03. | Stifel reiterates Buy rating on MapLight Therapeutics stock | 1 | Investing.com | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.03. | MapLight Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 26.03. | MapLight Therapeutics, Inc. GAAP EPS of -$2.47 | 1 | Seeking Alpha | ||
| 26.03. | MapLight Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 26.03. | MapLight Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.03. | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 671 | GlobeNewswire (Europe) | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen | |
| 09.01. | MapLight Therapeutics: Aktie steigt nach beschleunigtem Zeitplan für klinische Studien | 1 | Investing.com Deutsch | ||
| 09.01. | MapLight Therapeutics zieht Zeitplan für Phase-2-Studienergebnisse vor | 2 | Investing.com Deutsch | ||
| 09.01. | MapLight Therapeutics accelerates timeline for Phase 2 trial results | 2 | Investing.com | ||
| 09.01. | MapLight Therapeutics, Inc.: MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 | 753 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing... ► Artikel lesen | |
| 09.01. | MapLight Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | MapLight Dims on FDA Nod | 1 | Baystreet.ca | ||
| 05.01. | FDA grants fast track designation to MapLight's Alzheimer's drug | 2 | Investing.com | ||
| 05.01. | MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status | 1 | RTTNews | ||
| 05.01. | MapLight Therapeutics, Inc.: MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis | 403 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. ("MapLight") (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast... ► Artikel lesen | |
| 16.12.25 | SandboxAQ und MapLight schließen 200-Millionen-Dollar-Allianz zur Erforschung von ZNS-Wirkstoffen | 1 | Investing.com Deutsch | ||
| 16.12.25 | SandboxAQ and MapLight form $200 million CNS drug discovery alliance | 2 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,915 | +1,60 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| EVOTEC | 5,390 | +14,68 % | Evotec: Aktivistischer Investor macht Druck - die Hintergründe | Die Aktie des Hamburger Wirkstoffforschers Evotec hat den Anlegern in den zurückliegenden Jahren nur wenig Freude bereitet. Der Titel rutschte sogar vor kurzem auf ein neues Mehrjahrestief ab. Das ruft... ► Artikel lesen | |
| MODERNA | 44,445 | +3,12 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| BIONTECH | 84,00 | +2,13 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| PRAXIS PRECISION MEDICINES | 339,50 | +7,18 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,850 | +0,96 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| ERASCA | 17,830 | +9,32 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| IMMUNOME | 22,810 | +0,88 % | Immunome: Q4 Earnings Insights | ||
| SANA BIOTECHNOLOGY | 3,470 | +8,27 % | Morning Market Movers: Avanos Medical, Sana Biotechnology, Credo Technology Group, Bloom Energy See Big Swings | BEIJING (dpa-AFX) - At 7:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,710 | +3,85 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,590 | +2,12 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,535 | -16,89 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| ARCELLX | 114,89 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 89,47 | +1,08 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,515 | +1,24 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
MAPLIGHT THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,020 (+3,88 %) liegt der Kurs bei 27,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.